Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7906.007 | 0.9171 | 0.7391 | 0.6194 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7906.007 | 0.5926 | -0.1406 | 0.6194 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7906.007 | 0.3541 | -0.6258 | 0.6194 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7906.007 | 0.1321 | -0.9238 | 0.6194 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7906.007 | 0.0772 | -0.9680 | 0.6194 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7907.043 | 1.2949 | 1.3429 | 1.6330 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7907.043 | 0.8338 | 0.7893 | 1.6330 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7907.043 | 1.0620 | 1.0750 | 1.6330 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7907.043 | 0.9145 | 0.8935 | 1.6330 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7907.043 | 1.0690 | 1.0834 | 1.6330 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7907.043 | 0.7255 | 0.6431 | 1.6330 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7907.043 | 0.7206 | 0.6364 | 1.6330 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7907.043 | 0.2298 | -0.1872 | 1.6330 | |
| MDA-MB-468 | TNBC | Basal A | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7907.043 | 0.9918 | 0.9899 | 1.6330 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9759.121 | 1.0366 | 1.0566 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9759.121 | 0.9837 | 0.9746 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9759.121 | 1.0079 | 1.0123 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9759.121 | 0.9632 | 0.9427 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9759.121 | 0.5303 | 0.2225 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9759.121 | 0.1634 | -0.5096 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9759.121 | 0.0405 | -0.8340 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9759.121 | 0.0382 | -0.8414 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 9759.121 | 0.0053 | -0.9658 | 1.2887 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9760.121 | 1.0920 | 1.1790 | 1.0265 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9760.121 | 1.0091 | 1.0177 | 1.0265 |